PE20071037A1 - SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA - Google Patents

SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA

Info

Publication number
PE20071037A1
PE20071037A1 PE2006001565A PE2006001565A PE20071037A1 PE 20071037 A1 PE20071037 A1 PE 20071037A1 PE 2006001565 A PE2006001565 A PE 2006001565A PE 2006001565 A PE2006001565 A PE 2006001565A PE 20071037 A1 PE20071037 A1 PE 20071037A1
Authority
PE
Peru
Prior art keywords
phenyl
urea
metoxy
pyrrolo
pyrimidin
Prior art date
Application number
PE2006001565A
Other languages
English (en)
Inventor
Tracy Lee Boyden
Feng Guo
Susan Deborah Lagreca
Douglas Alan Lorenz
Shanker Ravy Mysore
Franzanne Vreeland
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20071037A1 publication Critical patent/PE20071037A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA DISPERSION SOLIDA AMORFA DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA Y UN POLIMERO PARA AUMENTAR LA CONCENTRACION TAL COMO ACETATO SUCCINATO DE HIDROXIPROPIL METILCELULOSA, EN DONDE DICHO COMPUESTO DE UREA COMPRENDE ENTRE 10% Y 40% EN PESO DE LA DISPERSION SOLIDA AMORFA. DICHA DISPERSION SOLIDA AMORFA ESTA MEZCLADA CON MAS POLIMEROS PARA AUMENTAR LA CONCENTRACION TALES COMO ACETATO DE HIDROXIPROPIL METIL CELULOSA, HIDROXIPROPIL METIL CELULOSA, HIDROXIPROPIL CELULOSA, METIL CELULOSA, HIDROXIETIL METIL CELULOSA, ENTRE OTROS. DICHA COMPOSICION FARMACEUTICA ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS
PE2006001565A 2005-12-09 2006-12-06 SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA PE20071037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74907005P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
PE20071037A1 true PE20071037A1 (es) 2007-11-19

Family

ID=38123252

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001565A PE20071037A1 (es) 2005-12-09 2006-12-06 SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA

Country Status (8)

Country Link
AR (1) AR058293A1 (es)
DO (1) DOP2006000271A (es)
GT (1) GT200600496A (es)
NL (1) NL2000337A1 (es)
PE (1) PE20071037A1 (es)
TW (1) TW200733965A (es)
UY (1) UY29991A1 (es)
WO (1) WO2007066189A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699335A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg. Solid dispersion product containing n-aryl urea-based compound
BRPI0818340A2 (pt) * 2007-10-19 2015-04-22 Abbott Gmbh & Co Kg Produto de dispersão sólida de fármacos baseados em n-aril uréia
ES2570429T3 (es) * 2008-10-16 2016-05-18 Univ California Inhibidores de heteroaril quinasa de anillo condensado
CN102892768A (zh) 2009-12-30 2013-01-23 艾科尔公司 被取代的吡咯并氨基嘧啶化合物
CN103037843A (zh) * 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20140004192A1 (en) * 2012-04-13 2014-01-02 Ziopharm Oncology, Inc. Pharmaceutical formulations of indibulin and uses thereof
ME03300B (me) 2012-06-13 2019-07-20 Incyte Holdings Corp Supsтituisana triciklična jedinjenja као inhibiтori fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN107722012B (zh) * 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EA202092649A1 (ru) 2018-05-04 2021-06-21 Инсайт Корпорейшн Соли ингибитора fgfr
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives

Also Published As

Publication number Publication date
TW200733965A (en) 2007-09-16
NL2000337A1 (nl) 2007-06-12
GT200600496A (es) 2007-07-17
AR058293A1 (es) 2008-01-30
DOP2006000271A (es) 2007-08-15
WO2007066189A3 (en) 2008-08-14
WO2007066189A2 (en) 2007-06-14
UY29991A1 (es) 2007-07-31

Similar Documents

Publication Publication Date Title
PE20071037A1 (es) SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
BRPI0513841A (pt) composto, composição farmacêutica, e uso do composto
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
AR054581A1 (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
HN2005000484A (es) Nuevas composiciones farmaceuticas para el tratamiento de trastornos hiperproliferativos
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
CR11441A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
UY31219A1 (es) N-[3-(2,6-diclorofenil)-5-alquilo-1,2-oxazol-4-il carbamatos sustituidos y 1-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]ureas sustituidas asi como isomeros, sales farmacéuticas y usos de dichos compuestos
EA200970841A1 (ru) Фармацевтическое применение замещенных амидов
PE20070720A1 (es) Derivados de fenilo como antagonistas del receptor 3 de la histamina
DE602005013248D1 (de) Amidderivate von 3-phenyldihydropyrimidoä4,5-düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
EA201170829A1 (ru) Замещенные бициклические производные имидазола в качестве модуляторов гамма-секретазы
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201171008A1 (ru) Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
AR055319A1 (es) Derivados de isoquinoleina, composiciones farmaceuticas y usos
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
DK1843754T3 (da) Ny farmaceutisk sammensætning indeholdende candesartan-cilexetil som lipofilt krystallinsk stof
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
DE602006015449D1 (de) Verwendung von verbindungen zur induktion der synthese von sirt-proteinen bei der oder für die herstellung eines kosmetikums oder einer pharmazeutischen zusammensetzung

Legal Events

Date Code Title Description
FD Application declared void or lapsed